CTI BioPharma (CTIC) Sees Prelim. FY14 Revs at $60M; Guides FY15 Revenue Above Views
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
EPS Growth %: +100.0%
Financial Fact:
Total operating expenses: 33.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +100.0%
Financial Fact:
Total operating expenses: 33.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
CTI BioPharma (NASDAQ: CTIC) reports preliminary FY14 revenue of $60 million.
The company is also modeling FY15 revs of $55 to $72 million. Consensus estimates call for FY15 revs of $41.6 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Western Digital (WDC) posts FQ3 earnings, revenue beat; shares down
Create E-mail Alert Related Categories
Corporate News, Guidance, Hot Corp. News, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
